<DOC>
	<DOCNO>NCT00081588</DOCNO>
	<brief_summary>The primary objective TMC114-C215 study evaluate safety tolerability TMC114/RTV time . The secondary objective evaluate antiviral activity time evaluate immunological effect time .</brief_summary>
	<brief_title>An Open Label Trial TMC114/RTV HIV-1 Infected , Treatment-experienced Subjects .</brief_title>
	<detailed_description>The study continue 144 week study medication begin . For patient fail treatment , must participate TMC114-C213 TMC114-C202 least 12 week meet specific virologic failure criterion . It estimate approximately 150 patient may meet criterion . Major inclusion exclusion criterion list . For new patient , must prior antiretroviral therapy , include one nucleoside reverse transcriptase inhibitor ( NRTI ) , one non-nucleoside reverse transcriptase inhibitor ( NNRTI ) protease inhibitor ( PI ) . At least one primary PI mutation must present screen . Many center participate TMC114-C213 TMC-114 -C202 study also participate TMC114-C215 study . All sit chance recruit rollover patient TMC114-C215 study site list approval recruit new patient study . The recruitment new patient TMC114-C215 trial fully enrol . The TMC114-C202 TMC114-C213 complete patient enrol study . Two 300mg/100mg Darunavir/Ritonavir tablet twice daily 144 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<criteria>Previous participation TMC114C202 TMC114C213 trial Significant virologic failure participation trial Study participation treatment phase original trial total least 12 week TMC114C215 screen Patient agrees take TMC114/RTV least 2 antiretrovirals ( NRTIs ) , without T20 , baseline onwards Patient give inform consent Use disallow concomitant therapy Patient clinical laboratory evidence active liver disease , liver impairment/ dysfunction cirrhosis irrespective liver enzyme level Any active unstable medical condition , investigator 's opinion , would compromise subject 's safety Patient laboratory abnormality screen define ACTG grade scheme list protocol Patient withdraw consent TMC114C202 TMC114C213</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>TMC114-C215</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>HIV infection</keyword>
	<keyword>TMC114-C202</keyword>
	<keyword>TMC114-C213</keyword>
</DOC>